Aptamer Sciences Inc
Aptamer Sciences Inc, a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms. The company's platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics for cancer and neurological disorders. It offers AlloMAp and Bi-Functional Aptame (BiFAp) platform programs for therapeutics, as well… Read more
Aptamer Sciences Inc - Asset Resilience Ratio
Aptamer Sciences Inc (291650) has an Asset Resilience Ratio of 19.83% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Aptamer Sciences Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Aptamer Sciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩5.01 Billion | 19.83% |
| Total Liquid Assets | ₩5.01 Billion | 19.83% |
Asset Resilience Insights
- Good Liquidity Position: Aptamer Sciences Inc maintains a healthy 19.83% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Aptamer Sciences Inc Industry Peers by Asset Resilience Ratio
Compare Aptamer Sciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Aptamer Sciences Inc (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Aptamer Sciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 54.64% | ₩17.47 Billion | ₩31.98 Billion | -18.47pp |
| 2023-12-31 | 73.11% | ₩23.79 Billion | ₩32.54 Billion | -2.96pp |
| 2022-12-31 | 76.07% | ₩34.72 Billion | ₩45.65 Billion | +3.28pp |
| 2021-12-31 | 72.79% | ₩24.21 Billion | ₩33.26 Billion | -21.61pp |
| 2020-12-31 | 94.40% | ₩34.86 Billion | ₩36.93 Billion | +5.79pp |
| 2019-12-31 | 88.60% | ₩7.37 Billion | ₩8.32 Billion | -2.48pp |
| 2018-12-31 | 91.09% | ₩10.01 Billion | ₩10.99 Billion | -- |